{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:14:23Z","timestamp":1787004863988,"version":"build-2736575974"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical trials have revealed that sodium glucose cotransporter 2 (SGLT2)\n                    inhibitors suppress the onset of heart failure and cardiovascular death in\n                    diabetic patients. On the other hand, few reports have been published concerning\n                    such effects of dipeptidyl peptidase-4 (DPP-4) inhibitors. We undertook the\n                    present study to evaluate the effects of SGLT2 inhibitors and DPP-4 inhibitors\n                    on the advanced glycation end products (AGEs), well known as a risk factor for\n                    the development of cardiovascular disorders.<\/jats:p>\n                  <jats:p>Type 2 diabetes mellitus were divided into two groups and treated with either\n                    SGLT2 inhibitors or DPP-4 inhibitors for 3 months. Before and after the 3-month\n                    treatment period with each drug, the AGEs and diabetes-related parameters were\n                    measured. Methylglyoxal-derived hydroimidazolone-1 (MG-H1) was measured as one\n                    of the AGEs.<\/jats:p>\n                  <jats:p>In the SGLT2 inhibitor group, both the blood HbA1c and MG-H1 levels decreased\n                    significantly after the 3-month treatment period. In the DPP-4 inhibitor group,\n                    only the blood HbA1c level decreased significantly, with no significant change\n                    of the blood MG-H1 level.<\/jats:p>\n                  <jats:p>SGLT2 inhibitor reduced both the blood levels of HbA1c and AGEs (MG-H1).\n                    Considering that the blood levels of AGEs are associated with the risk of heart\n                    failure and cardiovascular disorders, the results of the present study suggest\n                    that the effect of SGLT2 inhibitors in suppressing cardiovascular death might be\n                    mediated by the reduction in the blood levels of AGEs induced by this class of\n                    drugs. DPP-4 inhibitors showed no significant effects on the blood levels of\n                    AGEs.<\/jats:p>","DOI":"10.1055\/a-2234-1797","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T19:26:01Z","timestamp":1706556361000},"page":"77-80","source":"Crossref","is-referenced-by-count":9,"title":["Effects of SGLT2 Inhibitors and DPP-4 Inhibitors on Advanced\n                    Glycation End Products"],"prefix":"10.1055","volume":"74","author":[{"given":"Masataka","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Motor Function and Metabolism, Research Center\n                    of Health, Physical Fitness and Sports, Nagoya University, Nagoya City, Aichi,\n                    Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Hisano","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Department of Integrated Health Sciences,\n                    Nagoya University, Nagoya City, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Data Science, Faculty of Science and Technology, Nanzan\n                    University, Nagoya City, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Akishima Clinic. Sakae, Naka-ku, Nagoya City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Motor Function and Metabolism, Research Center\n                    of Health, Physical Fitness and Sports, Nagoya University, Nagoya City, Aichi,\n                    Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Okinaka Memorial Institute for Medical Research, Tokyo,\n                    Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Miyata","sequence":"additional","affiliation":[{"name":"Office of Medical Education, School of Medicine, International\n                    University of Health and Welfare, Narita City, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.mam.2012.11.002","article-title":"Glucose transport families SLC5 and SLC50","volume":"34","author":"E M Wright","year":"2013","journal-title":"Mol Aspects Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"E M Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing\n                    glycaemia","volume":"14","author":"R A DeFronzo","year":"2012","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","article-title":"Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with\n                    type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, Phase\n                    3 study","volume":"30","author":"Y Seino","year":"2014","journal-title":"Current Medical Research & Opinion"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"EMPA-REG OUTCOME Investigators: Empagliflozin and Progression of Kidney Disease\n                    in Type 2 Diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"E Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2337\/dc11-0091","article-title":"Restriction of advanced glycation end products improves insulin resistance in\n                    human type 2 diabetes: potential role AGER 1, and SIRT 1","volume":"34","author":"J Uribarri","year":"2011","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1755-5922.2011.00264.x","article-title":"Serum levels of advanced glycation end products (AGEs) are inversely associated\n                    with the number and migratory activity of circulating endothelial progenitor\n                    cells in apparently healthy subjects","volume":"30","author":"S Ueda","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4\n                    inhibitors between Asians and non-Asians: a systematic review and\n                    meta-analysis","volume":"56","author":"Y G Kim","year":"2013","journal-title":"Diabetologia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1463-1326.2011.01380.x","article-title":"Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in\n                    type 2 diabetes: meta-analysis of randomized controlled trials","volume":"13","author":"K Esposito","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3164\/jcbn.15-132","article-title":"Non-invasive measurement of skin autofluorescence to evaluate diabetic\n                    complications","volume":"58","author":"M Yamanaka","year":"2016","journal-title":"J Clin Biochem Nutr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1755-5922.2011.00264.x","article-title":"Serum levels of advanced glycation end products (AGEs) are inversely associated\n                    with the number and migratory activity of circulating endothelial progenitor\n                    cells in apparently healthy subjects","volume":"30","author":"S Ueda","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/bbrc.1999.0625","article-title":"Advanced glycation endproducts accelerate calcification in microvascular\n                    pericytes","volume":"258","author":"S Yamagishi","year":"1999","journal-title":"Biophy Res Commun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5551\/jat.36293","article-title":"Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans","volume":"24","author":"N Tomosugi","year":"2017","journal-title":"J Atheroscler Thromb"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1007\/s13197-015-1851-y","article-title":"Advanced glycation End-products (AGEs): an emerging concern for processed food\n                    industries","volume":"52","author":"C Sharma","year":"2015","journal-title":"J Food Sci Technol"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2234-1797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:30:02Z","timestamp":1730788202000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2234-1797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":15,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2024,2,12]]},"published-print":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2234-1797","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]}}}